Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Expression of steroid and xenobiotic receptor in uterine carcinosarcoma, leiomyosarcoma and endometrial stromal sarcoma.

Yue X, Utsunomiya H, Akahira JI, Suzuki F, Ito K, Nagase S, Sasano H, Yaegashi N.

Oncol Lett. 2013 Mar;5(3):835-839. Epub 2012 Dec 28.

2.

Steroid and Xenobiotic Receptor (SXR) as a possible prognostic marker in epithelial ovarian cancer.

Yue X, Akahira J, Utsunomiya H, Miki Y, Takahashi N, Niikura H, Ito K, Sasano H, Okamura K, Yaegashi N.

Pathol Int. 2010 May;60(5):400-6. doi: 10.1111/j.1440-1827.2010.02546.x.

PMID:
20518891
3.

Immunohistochemical studies on uterine carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma: expression and prognostic importance of ten different markers.

Koivisto-Korander R, Butzow R, Koivisto AM, Leminen A.

Tumour Biol. 2011 Jun;32(3):451-9. doi: 10.1007/s13277-010-0138-1. Epub 2010 Dec 16.

PMID:
21161468
4.

Retrospective analysis of 80 cases with uterine carcinosarcoma, leiomyosarcoma and endometrial stromal sarcoma in China, 1988-2007.

Gao Y, Meng H, Zhang Y, Jiao T, Hui N.

Int J Clin Exp Pathol. 2014 Mar 15;7(4):1616-24. eCollection 2014.

5.

Diagnosis and surgical therapy of uterine sarcoma.

Vrzic-Petronijevic S, Likic-Ladjevic I, Petronijevic M, Argirovic R, Ladjevic N.

Acta Chir Iugosl. 2006;53(3):67-72.

PMID:
17338203
6.

Expression of the steroid and xenobiotic receptor and its possible target gene, organic anion transporting polypeptide-A, in human breast carcinoma.

Miki Y, Suzuki T, Kitada K, Yabuki N, Shibuya R, Moriya T, Ishida T, Ohuchi N, Blumberg B, Sasano H.

Cancer Res. 2006 Jan 1;66(1):535-42.

7.

Prognoses and prognostic factors of carcinosarcoma, endometrial stromal sarcoma and uterine leiomyosarcoma: a comparison with uterine endometrial adenocarcinoma.

Akahira J, Tokunaga H, Toyoshima M, Takano T, Nagase S, Yoshinaga K, Tase T, Wada Y, Ito K, Niikura H, Yamada H, Sato A, Sasano H, Yaegashi N.

Oncology. 2006;71(5-6):333-40. Epub 2007 Aug 9.

PMID:
17690557
8.

Uterine sarcomas in South African black women: a clinicopathologic study with ethnic considerations.

Amant F, Dreyer L, Makin J, Vergote I, Lindeque BG.

Eur J Gynaecol Oncol. 2001;22(3):194-200.

PMID:
11501770
9.

The prognostic relevance of histological type in uterine sarcomas: a Cooperation Task Force (CTF) multivariate analysis of 249 cases.

Gadducci A, Sartori E, Landoni F, Zola P, Maggino T, Cosio S, Tisi G, Lissoni A, Ferrero AM, Cristofani R.

Eur J Gynaecol Oncol. 2002;23(4):295-9.

PMID:
12214727
10.

Steroid and xenobiotic receptor in human esophageal squamous cell carcinoma: a potent prognostic factor.

Takeyama D, Miki Y, Fujishima F, Suzuki T, Akahira J, Hata S, Miyata G, Satomi S, Sasano H.

Cancer Sci. 2010 Feb;101(2):543-9. doi: 10.1111/j.1349-7006.2009.01380.x. Epub 2009 Oct 3.

11.

Preoperative diagnosis and treatment results in 106 patients with uterine sarcoma in Hokkaido, Japan.

Sagae S, Yamashita K, Ishioka S, Nishioka Y, Terasawa K, Mori M, Yamashiro K, Kanemoto T, Kudo R.

Oncology. 2004;67(1):33-9.

PMID:
15459493
12.

Association of steroid and xenobiotic receptor (SXR) and multidrug resistance 1 (MDR1) gene expression with survival among patients with invasive bladder carcinoma.

Rioja J, Bandrés E, Rosell Costa D, Rincón A, López I, Zudaire Bergera JJ, García Foncillas J, Gil MJ, Panizo A, Plaza L, Rioja LA, Berián Polo JM.

BJU Int. 2011 Jun;107(11):1833-8. doi: 10.1111/j.1464-410X.2010.09653.x. Epub 2010 Sep 14.

13.
14.

Uterine leiomyosarcoma and endometrial stromal sarcoma have unique miRNA signatures.

Ravid Y, Formanski M, Smith Y, Reich R, Davidson B.

Gynecol Oncol. 2016 Mar;140(3):512-7. doi: 10.1016/j.ygyno.2016.01.001. Epub 2016 Jan 6.

PMID:
26768834
15.

Immunohistochemical panel to differentiate endometrial stromal sarcoma, uterine leiomyosarcoma and leiomyoma: something old and something new.

Hwang H, Matsuo K, Duncan K, Pakzamir E, Pham HQ, Correa A, Fedenko A, Mhawech-Fauceglia P.

J Clin Pathol. 2015 Sep;68(9):710-7. doi: 10.1136/jclinpath-2015-202915. Epub 2015 May 19.

PMID:
25991737
16.

Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma.

Leitao MM, Soslow RA, Nonaka D, Olshen AB, Aghajanian C, Sabbatini P, Dupont J, Hensley M, Sonoda Y, Barakat RR, Anderson S.

Cancer. 2004 Sep 15;101(6):1455-62.

17.

ERBB-2 gene overexpression and amplification in uterine sarcomas.

Amant F, Vloeberghs V, Woestenborghs H, Debiec-Rychter M, Verbist L, Moerman P, Vergote I.

Gynecol Oncol. 2004 Dec;95(3):583-7.

PMID:
15581967
18.

Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874).

Reed NS, Mangioni C, Malmström H, Scarfone G, Poveda A, Pecorelli S, Tateo S, Franchi M, Jobsen JJ, Coens C, Teodorovic I, Vergote I, Vermorken JB; European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group.

Eur J Cancer. 2008 Apr;44(6):808-18. doi: 10.1016/j.ejca.2008.01.019. Epub 2008 Apr 2. Erratum in: Eur J Cancer. 2008 Jul;44(11):1612.

PMID:
18378136
19.

Estrogen and progesterone receptor expression in patients with uterine leiomyosarcoma and correlation with different clinicopathological parameters.

Bodner K, Bodner-Adler B, Kimberger O, Czerwenka K, Leodolter S, Mayerhofer K.

Anticancer Res. 2003 Jan-Feb;23(1B):729-32.

PMID:
12680175
20.

[Chemotherapy and hormone therapy for uterine sarcomas].

Yamashita H, Arai H, Aoki D.

Gan To Kagaku Ryoho. 2012 May;39(5):722-5. Japanese.

PMID:
22584323

Supplemental Content

Support Center